Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02210689
Recruitment Status : Completed
First Posted : August 7, 2014
Last Update Posted : March 19, 2015
Sponsor:
Collaborator:
Watson Laboratories, Inc.
Information provided by (Responsible Party):
Actavis Inc.

Tracking Information
First Submitted Date  ICMJE August 4, 2014
First Posted Date  ICMJE August 7, 2014
Last Update Posted Date March 19, 2015
Study Start Date  ICMJE January 2014
Actual Primary Completion Date October 2014   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 5, 2014)
Both clinical and a bacteriological cure (Nugent score <4), evaluated at Visit 2 Test-of-cure (study day 22-30). [ Time Frame: 22 to 30 days ]
Clinical Cure is defined as resolution of clinical signs and symptoms from entry visit as follows:
  1. The original discharge characteristic of bacterial vaginosis has returned to a normal physiological vaginal discharge which varies in appearance and consistency depending on the menstrual cycle,
  2. The whiff test is negative for any amine ("fishy") odor,
  3. The saline wet mount is negative for clue cells,
  4. Vaginal fluid pH is < 4.7, using pH paper that measures from 3.6 to 6.1. A bacteriological cure is defined as a Nugent score < 4.
The system will use a 0-4 scale for evaluation of vaginal flora, based on the weighted sum of the following 3 bacterial morphotypes scores calculated from slide examination under oil immersion field (See appendix 11.2) :
  1. Lactobacillus: large gram positive rods,
  2. Gardenella / Bacteroides spp: Small gram variable coccobacilli/small Gram negative rods,
  3. Mobiluncus spp.: thin, curved Gram variable rods.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02210689 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women
Official Title  ICMJE Not Provided
Brief Summary A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and both active treatments to a placebo control in the treatment of bacterial vaginosis in non-pregnant women.
Detailed Description

The study treatment period will be 1 day. Subject participation is 22-30 days. Expected study duration is 10 to 12 months. The study will enroll in up to 30 clinical sites.

Test Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)

Reference Product: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)

Placebo Control: One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)

Dose and Mode A single applicator of investigational product cream will be administered of Administration once intravaginally at any time of the day. The subject participation is 22-30 days (drug administration for 1 day).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • BACTERIAL VAGINOSIS
  • Signs and Symptoms to be Evaluated and Recorded Include:
  • Vaginal Discharge: Color, Odor, and Consistency;
  • Vulvovaginal Itching and Irritation (Subjective): Absent, Mild, Moderate, or Severe
  • Vulvovaginal Inflammation (Objective): Absent, Mild, Moderate, or Severe.
Intervention  ICMJE Drug: clindamycin phosphate vaginal cream 2%
Other Name: Placebo
Study Arms  ICMJE
  • Experimental: test product
    One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
    Intervention: Drug: clindamycin phosphate vaginal cream 2%
  • Active Comparator: reference product
    One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
    Intervention: Drug: clindamycin phosphate vaginal cream 2%
  • Placebo Comparator: placebo
    One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 18, 2015)
604
Original Estimated Enrollment  ICMJE
 (submitted: August 5, 2014)
660
Actual Study Completion Date  ICMJE December 2014
Actual Primary Completion Date October 2014   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects must be willing and able to understand and comply with the requirements of the protocol, including attendance at the required study visits and must provide the written informed consent prior to any study related procedure being performed.
  2. Healthy non-pregnant female aged ≥ 18 years with no known medical conditions that, in the investigator's opinion, may interfere with study participation or may interfere with the evaluation of bacterial vaginosis.
  3. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to the Visit 2 Test-of-cure. For the purpose of this study the following are considered acceptable methods of birth control:

    • Oral or injectable contraceptives
    • Contraceptive patches
    • Depo-Provera® (stabilized for at least 3 months); Implanon™ (contraceptive implant), or abstinence with one of the above-listed methods of birth control should the Subject become sexually active.
    • A sterile sexual partner is NOT considered an adequate form of birth control.
    • Willing to refrain from sexual intercourse on study days 1-7 and for 48 hours prior to Visit 2 Test-of-cure.
  4. Willing to refrain from using any vaginal product (e.g., spermicide, tampon, douche, diaphragm, or condom) other than study product, on study Days 1-7, for 48 hours prior to the first dose of study product, and for 48 hours prior to Visit 2 Test-of-cure.
  5. Diagnosis of bacterial vaginosis, defined as the presence of all of the following:

    • Clinical diagnosis of bacterial vaginosis (e.g., thin, homogenous vaginal discharge associated with minimal or absent pruritus or inflammation AND
    • Saline wet mount of vaginal discharge demonstrating the proportion of clue cell to be ≥ 20% of the total epithelial cells AND
    • Vaginal pH > 4.5, using pH paper that measures from 4.0-6.0 AND
    • Positive "whiff test" after addition of a drop of 10% KOH to vaginal discharge)
    • Gram stain Nugent score ≥ 4 on first day of dosing (study day 1) (per Table 1 below).
    • Table 1: Nugent Scoring System (0-10) for Gram-stained Vaginal Smears (a)
    • Score (b) Lactobacillus morphotypes Gardnerella and Bacteroides spp. morphotypes Curved gram-variable rods
    • 0 4+ 0 0
    • 1 3+ 1+ 1+ or 2+
    • 2 2+ 2+ 3+ or 4+
    • 3 1+ 3+
    • 4 0 4+

Source: Nugent, R. P., M. A. Krohn, and S. L. Hillier. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J. Clin. Microbial. 1991; 29: 297-301.

  • Morphotypes are scored as the average number seen per oil immersion field. Note that less weight is given to curved gram-variable rods. Total score = lactobacilli + G. vaginalis and Bacteroides spp/ + curved rods.
  • 0, No morphotypes present; 1, <1 morphotype present; 2, 1 to 4 morphotypes present; 3, 5 to 30 morphotypes present; 4, 30 or more morphotypes present.

Exclusion Criteria:

  1. Female subjects who are pregnant, nursing or planning to become pregnant during study participation.
  2. Menstruating when diagnosis of bacterial vaginosis is determined at Baseline visit.
  3. Primary or secondary immunodeficiency.
  4. Severe liver disease.
  5. History of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.
  6. Evidence of any vulvovaginitis other than bacterial vaginosis. (e.g., candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Herpes simplex).
  7. Subjects with visible signs of HPV infection, i.e. visible warts.
  8. Subject with another vaginal or vulvar condition, which would confound the interpretation of clinical response.
  9. Subject will be under treatment during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
  10. History of hypersensitivity to clindamycin, lincomycin, or any of the components of the vaginal creams.
  11. Use within 2 weeks prior to baseline of 1) topical or systemic antibiotics or 2) topical or systemic antifungal.
  12. Use of spermicides, tampons, douches, diaphragms, condoms within 48 hours of the baseline visit.
  13. Concurrent use of systemic corticosteroids or systemic antibiotics.
  14. Unwilling or unable to comply with the protocol requirements.
  15. Subjects who have participated in an investigational drug study (i.e., subjects have been treated with an investigational drug) within 30 days prior to baseline will be excluded from study participation. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion.
  16. Subjects who have been previously enrolled in this study.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Dominican Republic,   Puerto Rico,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02210689
Other Study ID Numbers  ICMJE 13-1052
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Actavis Inc.
Study Sponsor  ICMJE Actavis Inc.
Collaborators  ICMJE Watson Laboratories, Inc.
Investigators  ICMJE
Study Director: nageshwar r thudi, Ph.D., CCRP Actavis Inc.
PRS Account Actavis Inc.
Verification Date March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP